| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032667A1 Ether-type gla-60 analogues |
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032646A2 Sulfonamide derivatives |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032197A2 Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |
| 05/10/2001 | WO2001032166A1 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032163A1 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO1999002514A3 Epothilone derivatives |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2388657A1 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097147A1 Novel angiogenesis inhibitors |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097127A1 Diacylhydrazine derivatives as integrin inhibitors |
| 05/09/2001 | EP1096924A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 05/09/2001 | CN1294579A Sulfonamide-contg. indole compounds |
| 05/09/2001 | CN1294011A 'Gumeihuichun Dan' |
| 05/09/2001 | CN1294007A Medicine for treating bone fracture and osteopathy |
| 05/09/2001 | CN1294003A Chinese patent medicine for promoting blood air circulation and building up bone and its preparing process |
| 05/09/2001 | CN1293998A Chinese medicine for treating diseases of cervical or lumbar vertebra |
| 05/09/2001 | CN1293997A Powdered medicine for treating hyperosteogeny to cervical or lumbar vertebra |
| 05/09/2001 | CN1293988A Chinese medicine 'Shexianfengshi wan' |
| 05/09/2001 | CN1293984A Medical wind for treating rheumatism |
| 05/09/2001 | CN1293976A Composite Chinese medicine for treating diseases caused by wind and cold |
| 05/09/2001 | CN1293974A Exterior-applied Chinese medicine for setting up bone |
| 05/09/2001 | CN1065438C Cyclic adhesion inhibitors |
| 05/09/2001 | CN1065437C Medicine for treating ischialgia disease |
| 05/08/2001 | US6229029 11β-aryl substituted 14,17-ethanoestratriens, method for the production of these compounds and their use in the production of medicaments |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6229016 Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030828A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | WO2001030811A2 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis |
| 05/03/2001 | WO2001030798A1 Transgenic mice containing trp gene disruptions |
| 05/03/2001 | WO2001030788A1 Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030778A1 Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030357A1 Hormonal composition based on a progesterone and an oestrogen and use thereof |
| 05/03/2001 | WO2001030356A1 Hormonal composition based on a progestational agent and an oestrogen and use thereof |
| 05/03/2001 | WO2001030318A1 Oral solution containing galanthamine and a sweetening agent |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2000077168A3 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000068263A3 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 05/03/2001 | WO2000066107A3 Antimalarian agents for the treatment of asthma |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE19950113A1 Tricalciumphosphat-haltiges Hydroxylapatit-Material Containing tricalcium phosphate hydroxyapatite material |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388942A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |